biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Jan 14, 2019 4:00pm

130 Views

Post# 29229752

RE:RE:Pep Talk - Protein Science Week

"Do you think this will equate to having hard data in hand and released to the public in 2020?"

Not according to the timeline of the Phase 1b trial presented on slide 12.

".......and will that be inclusive of herceptin"

My understanding is that this Phase 1b is planned to use the xB3-herceptin fusion. But plans could change between now and first in human trial approval.

BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale